Characterization of Bimetallic Fe-Ru Oxide Nanoparticles Prepared by Liquid-Phase Plasma Method

The bimetallic Fe-Ru oxide nanoparticles were synthesized in the liquid-phase plasma (LPP) method which employed iron chloride and ruthenium chloride as precursors. The active species (OH·, H α , H β , and O I ) and the iron and ruthenium ions were observed in the plasma field created by the LPP pro...

Full description

Saved in:
Bibliographic Details
Published in:Nanoscale research letters 2016-12, Vol.11 (1), p.344-8, Article 344
Main Authors: Lee, Sung-Jin, Lee, Heon, Jeon, Ki-Joon, Park, Hyunwoong, Park, Young-Kwon, Jung, Sang-Chul
Format: Article
Language:English
Subjects:
Bimetals
Chemistry and Materials Science
Chlorides
EMN Meeting
Iron
Materials Science
Molecular Medicine
Nano Express
Nanochemistry
Nanoparticles
Nanoscale Science and Technology
Nanotechnology
Nanotechnology and Microengineering
Oxides
Precursors
Progressions
Ruthenium
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The bimetallic Fe-Ru oxide nanoparticles were synthesized in the liquid-phase plasma (LPP) method which employed iron chloride and ruthenium chloride as precursors. The active species (OH·, H α , H β , and O I ) and the iron and ruthenium ions were observed in the plasma field created by the LPP process. The spherical-shaped bimetallic Fe-Ru oxide nanoparticles were synthesized by the LPP reaction, and the size of the particles was growing along with the progression of the LPP reaction. The synthesized bimetallic Fe-Ru oxide nanoparticles were comprised of Fe 2 O 3 , Fe 3 O 4 , RuO, and RuO 2 . Ruthenium had a higher reduction potential than iron and resulted in higher ruthenium composition in the synthesized bimetallic nanoparticles. The control of the molar ratio of the precursors in the reactant solution was found to be employed as a means to control the composition of the elements in bimetallic nanoparticles.
ISSN:1931-7573
1556-276X
DOI:10.1186/s11671-016-1557-8